DLA
EXAS

Douglas Lane & Associates’s Exact Sciences EXAS Stock Holding History

Douglas Lane & Associates’s Portfolio EXAS Stock Details EXAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-6,000
Closed -$409K – 235
2024
Q3 		$409K Buy
+6,000
New +$339K 0.01% 196

Other funds holding EXAS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Douglas Lane & Associates's EXAS Position: Q4 2024 in Review

Douglas Lane & Associates sold out of Exact Sciences (EXAS) in Q4 2024, closing a stake of 6,000 shares — an estimated $409K sold.

Douglas Lane & Associates first reported a position in EXAS in Q3 2024 and held it in 1 quarter. The position peaked at $409K in Q3 2024. 594 funds tracked by Wall St. Rank hold EXAS as of Q4 2024.

  • Douglas Lane & Associates reported no remaining Exact Sciences position as of Q4 2024 after selling out during the quarter.
  • Douglas Lane & Associates sold 6,000 Exact Sciences shares in Q4 2024, an estimated $409K.
  • Douglas Lane & Associates first reported a position in Exact Sciences in Q3 2024 and held it in 1 quarter.
  • Douglas Lane & Associates's Exact Sciences position peaked at $409K in Q3 2024.
  • 594 funds tracked by Wall St. Rank held Exact Sciences as of Q4 2024.

Based on Douglas Lane & Associates's 13F filing for Q4 2024, filed 8 Jan 2025.